Tuesday, September 25, 2018
Company News: Page (1) of 1 - 08/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
- China FDA (CFDA) import drug registration priority review of EVOMELAŽ in progress and preparations continue for its commercial launch in China- CFDA review in progress for MarqiboŽ and ZevalinŽ- Ent...
(August 14, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:USA,China, Inc.,Science,Medical,Cancer,Business,china,Other,
Related Sites:
Related Newsletter:



Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines